{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:04:08Z","timestamp":1772136248365,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-70296-8","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T12:35:56Z","timestamp":1724157356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation"],"prefix":"10.1038","volume":"14","author":[{"given":"Ayana","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Katsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Okanoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanji","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kikuko","family":"Amagase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"70296_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003 (2023).","journal-title":"J. Hepatol."},{"key":"70296_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N. Engl. J. Med. 390, 497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000 (2024).","journal-title":"N. Engl. J. Med."},{"key":"70296_CR3","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3390\/biomedicines10040901","volume":"10","author":"A Umemura","year":"2022","unstructured":"Umemura, A. et al. Potential therapeutic targets and promising agents for combating NAFLD. Biomedicines 10, 901. https:\/\/doi.org\/10.3390\/biomedicines10040901 (2022).","journal-title":"Biomedicines"},{"key":"70296_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jhep.2020.03.011","volume":"73","author":"S Wang","year":"2020","unstructured":"Wang, S. & Friedman, S. L. Hepatic fibrosis: A convergent response to liver injury that is reversible. J. Hepatol. 73, 210\u2013211. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.011 (2020).","journal-title":"J. Hepatol."},{"key":"70296_CR5","first-page":"65","volume":"87","author":"G Buniatian","year":"1996","unstructured":"Buniatian, G., Hamprecht, B. & Gebhardt, R. Glial fibrillary acidic protein as a marker of perisinusoidal stellate cells that can distinguish between the normal and myofibroblast-like phenotypes. Biol. Cell 87, 65\u201373 (1996).","journal-title":"Biol. Cell"},{"key":"70296_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1046\/j.1365-2184.2003.00287.x","volume":"36","author":"GH Buniatian","year":"2003","unstructured":"Buniatian, G. H. Stages of activation of hepatic stellate cells: Effects of ellagic acid, an inhibiter of liver fibrosis, on their differentiation in culture. Cell Prolif. 36, 307\u2013319. https:\/\/doi.org\/10.1046\/j.1365-2184.2003.00287.x (2003).","journal-title":"Cell Prolif."},{"key":"70296_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/s0168-8278(96)80269-8","volume":"24","author":"K Neubauer","year":"1996","unstructured":"Neubauer, K., Knittel, T., Aurisch, S., Fellmer, P. & Ramadori, G. Glial fibrillary acidic protein: A cell type specific marker for Ito cells in vivo and in vitro. J. Hepatol. 24, 719\u2013730. https:\/\/doi.org\/10.1016\/s0168-8278(96)80269-8 (1996).","journal-title":"J. Hepatol."},{"key":"70296_CR8","first-page":"193","volume":"110","author":"S Morini","year":"2005","unstructured":"Morini, S. et al. GFAP expression in the liver as an early marker of stellate cells activation. Ital. J. Anat. Embryol. 110, 193\u2013207 (2005).","journal-title":"Ital. J. Anat. Embryol."},{"key":"70296_CR9","doi-asserted-by":"publisher","first-page":"8812","DOI":"10.1038\/srep08812","volume":"5","author":"C McKee","year":"2015","unstructured":"McKee, C. et al. Amphiregulin activates human hepatic stellate cells and is upregulated in non alcoholic steatohepatitis. Sci. Rep. 5, 8812. https:\/\/doi.org\/10.1038\/srep08812 (2015).","journal-title":"Sci. Rep."},{"key":"70296_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1053\/j.gastro.2004.11.006","volume":"128","author":"C Berasain","year":"2005","unstructured":"Berasain, C. et al. Amphiregulin: An early trigger of liver regeneration in mice. Gastroenterology 128, 424\u2013432. https:\/\/doi.org\/10.1053\/j.gastro.2004.11.006 (2005).","journal-title":"Gastroenterology"},{"key":"70296_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1039\/c3np20126k","volume":"30","author":"KB Kim","year":"2013","unstructured":"Kim, K. B. & Crews, C. M. From epoxomicin to carfilzomib: Chemistry, biology, and medical outcomes. Nat. Prod. Rep. 30, 600\u2013604. https:\/\/doi.org\/10.1039\/c3np20126k (2013).","journal-title":"Nat. Prod. Rep."},{"key":"70296_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.21036","volume":"43","author":"A Anan","year":"2006","unstructured":"Anan, A. et al. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 43, 335\u2013344. https:\/\/doi.org\/10.1002\/hep.21036 (2006).","journal-title":"Hepatology"},{"key":"70296_CR13","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","volume":"12","author":"RC Kane","year":"2006","unstructured":"Kane, R. C., Farrell, A. T., Sridhara, R. & Pazdur, R. United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res. 12, 2955\u20132960. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0170 (2006).","journal-title":"Clin. Cancer Res."},{"key":"70296_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10637-010-9532-1","volume":"30","author":"GP Kim","year":"2012","unstructured":"Kim, G. P. et al. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest. New Drugs 30, 387\u2013394. https:\/\/doi.org\/10.1007\/s10637-010-9532-1 (2012).","journal-title":"Invest. New Drugs"},{"key":"70296_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1021\/tx050313d","volume":"19","author":"J Labutti","year":"2006","unstructured":"Labutti, J. et al. Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: Contributions from reactive oxygen species in this novel cytochrome P450 reaction. Chem. Res. Toxicol. 19, 539\u2013546. https:\/\/doi.org\/10.1021\/tx050313d (2006).","journal-title":"Chem. Res. Toxicol."},{"key":"70296_CR16","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1124\/dmd.111.039164","volume":"39","author":"J Yang","year":"2011","unstructured":"Yang, J. et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab. Dispos. 39, 1873\u20131882. https:\/\/doi.org\/10.1124\/dmd.111.039164 (2011).","journal-title":"Drug Metab. Dispos."},{"key":"70296_CR17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s00535-012-0675-z","volume":"48","author":"I Saeki","year":"2013","unstructured":"Saeki, I. et al. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis. J. Gastroenterol. 48, 738\u2013750. https:\/\/doi.org\/10.1007\/s00535-012-0675-z (2013).","journal-title":"J. Gastroenterol."},{"key":"70296_CR18","doi-asserted-by":"publisher","first-page":"G709","DOI":"10.1152\/ajpgi.00126.2006","volume":"291","author":"A Anan","year":"2006","unstructured":"Anan, A. et al. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. Am. J. Physiol. Gastrointest. Liver Physiol. 291, G709-716. https:\/\/doi.org\/10.1152\/ajpgi.00126.2006 (2006).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"70296_CR19","doi-asserted-by":"publisher","first-page":"e21877","DOI":"10.1002\/jbt.21877","volume":"31","author":"A Alanazi","year":"2017","unstructured":"Alanazi, A. et al. Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen-induced hepatotoxicity in mice. J. Biochem. Mol. Toxicol. 31, e21877. https:\/\/doi.org\/10.1002\/jbt.21877 (2017).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"70296_CR20","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1016\/j.stemcr.2021.10.004","volume":"16","author":"M Roudaut","year":"2021","unstructured":"Roudaut, M. et al. PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs. Stem Cell Rep. 16, 2958\u20132972. https:\/\/doi.org\/10.1016\/j.stemcr.2021.10.004 (2021).","journal-title":"Stem Cell Rep."},{"key":"70296_CR21","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1126\/science.2466334","volume":"243","author":"M Shoyab","year":"1989","unstructured":"Shoyab, M., Plowman, G. D., McDonald, V. L., Bradley, J. G. & Todaro, G. J. Structure and function of human amphiregulin: A member of the epidermal growth factor family. Science 243, 1074\u20131076. https:\/\/doi.org\/10.1126\/science.2466334 (1989).","journal-title":"Science"},{"key":"70296_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/jcp.1041590115","volume":"159","author":"M Piepkorn","year":"1994","unstructured":"Piepkorn, M., Lo, C. & Plowman, G. Amphiregulin-dependent proliferation of cultured human keratinocytes: Autocrine growth, the effects of exogenous recombinant cytokine, and apparent requirement for heparin-like glycosaminoglycans. J. Cell. Physiol. 159, 114\u2013120. https:\/\/doi.org\/10.1002\/jcp.1041590115 (1994).","journal-title":"J. Cell. Physiol."},{"key":"70296_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/jcp.1041530114","volume":"153","author":"S Li","year":"1992","unstructured":"Li, S., Plowman, G. D., Buckley, S. D. & Shipley, G. D. Heparin inhibition of autonomous growth implicates amphiregulin as an autocrine growth factor for normal human mammary epithelial cells. J. Cell. Physiol. 153, 103\u2013111. https:\/\/doi.org\/10.1002\/jcp.1041530114 (1992).","journal-title":"J. Cell. Physiol."},{"key":"70296_CR24","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/hep.22437","volume":"48","author":"MJ Perugorria","year":"2008","unstructured":"Perugorria, M. J. et al. The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology 48, 1251\u20131261. https:\/\/doi.org\/10.1002\/hep.22437 (2008).","journal-title":"Hepatology"},{"key":"70296_CR25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1159\/000341705","volume":"30","author":"C Berasain","year":"2012","unstructured":"Berasain, C. et al. Epidermal growth factor receptor signaling in hepatocellular carcinoma: Inflammatory activation and a new intracellular regulatory mechanism. Dig. Dis. 30, 524\u2013531. https:\/\/doi.org\/10.1159\/000341705 (2012).","journal-title":"Dig. Dis."},{"key":"70296_CR26","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo, S. D. et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67, 6383\u20136391. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4086 (2007).","journal-title":"Cancer Res."},{"key":"70296_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/hep.510270514","volume":"27","author":"C Hellerbrand","year":"1998","unstructured":"Hellerbrand, C. et al. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology 27, 1285\u20131295. https:\/\/doi.org\/10.1002\/hep.510270514 (1998).","journal-title":"Hepatology"},{"key":"70296_CR28","unstructured":"NF-kB Target Genes, <https:\/\/www.bu.edu\/nf-kb\/gene-resources\/target-genes\/>"},{"key":"70296_CR29","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1136\/gut.2005.082701","volume":"55","author":"E Novo","year":"2006","unstructured":"Novo, E. et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: Resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 55, 1174\u20131182. https:\/\/doi.org\/10.1136\/gut.2005.082701 (2006).","journal-title":"Gut"},{"key":"70296_CR30","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1053\/j.gastro.2021.12.250","volume":"162","author":"T Qian","year":"2022","unstructured":"Qian, T. et al. Molecular signature predictive of long-term liver fibrosis progression to inform antifibrotic drug development. Gastroenterology 162, 1210\u20131225. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.250 (2022).","journal-title":"Gastroenterology"},{"key":"70296_CR31","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/nm1663","volume":"13","author":"E Seki","year":"2007","unstructured":"Seki, E. et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 13, 1324\u20131332. https:\/\/doi.org\/10.1038\/nm1663 (2007).","journal-title":"Nat. Med."},{"key":"70296_CR32","doi-asserted-by":"publisher","first-page":"13354","DOI":"10.3390\/ijms222413354","volume":"22","author":"S Kataoka","year":"2021","unstructured":"Kataoka, S. et al. Honokiol acts as a potent anti-fibrotic agent in the liver through inhibition of tgf-beta1\/SMAD signaling and autophagy in hepatic stellate cells. Int. J. Mol. Sci. 22, 13354. https:\/\/doi.org\/10.3390\/ijms222413354 (2021).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70296-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T12:38:12Z","timestamp":1724157492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70296-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["70296"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-70296-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4453616\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Itoh Y received Speakers\u2019 fee from ONO PHARMACEUTICAL CO., LTD. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19288"}}